Tailored diuretic treatment for patients with acute heart failure
Official title: TAILOR-AHF: Randomized Trial Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients
Run by Zuyderland Medisch Centrum · NCT06092437 · Data updated 2026-11-12
This study tests if a personalized diuretic treatment based on urine sodium levels can help people with acute heart failure feel better faster than standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 556 (estimated) |
| Sponsor | Zuyderland Medisch Centrum Academic / other |
| Locations | 2 sites (Heerlen, Limburg and 1 other locations) |
| Status | Recruiting |
| Started | February 27, 2023 |
| Main results expected | June 27, 2026 |
| Study ends | August 27, 2026 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT06092437 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old diagnosed with acutely decompensated heart failure requiring intravenous diuretics.
✕Probably not a fit
Patients with terminal renal insufficiency or those requiring intensive care upon admission may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates a tailored diuretic algorithm based on urinary sodium levels in patients with acutely decompensated heart failure. The study aims to determine if this personalized approach can lead to faster and more complete decongestion compared to standard care, ultimately improving patient outcomes. Participants will be randomly assigned to receive either the tailored treatment or usual care, with their responses monitored to assess effectiveness and safety. The trial is designed to provide evidence for implementing urinary sodium as a biomarker in diuretic therapy.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates and reduced heart failure events for patients with acute heart failure.
How similar studies have gone: While the use of urinary sodium as a biomarker is promising, this specific tailored approach is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years; * HF (HFrEF, HFmrEF or HFpEF) diagnosed according to the 2021 HF Guidelines of the European Society of Cardiology \[5\]; * Presentation with AHF meaning at least one symptom (dyspnea, orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography) of AHF; * An elevated NT-proBNP \>300pg/ml; * Requiring the need for iv diuretics. Exclusion Criteria: * Terminal renal insufficiency defined as: dialysis patients or eGFR (estimated glomerular filtration rate) \< 10 mL/min/1.73 m2; * Patients included in other investigational studies regarding heart failure. * Presentation with cardiogenic shock or respiratory insufficiency or another reason requiring admission to the intensive care unit upon admission (IC transfer later in the hospitalization is not an exclusion).
Where it's running
-
Zuyderland MC
Heerlen, Limburg, Netherlands Recruiting -
Amphia ziekenhuis
Breda, North Brabant, Netherlands Recruiting
Study contacts
- Study coordinator: Sandra van Wijk, MD, PhD
- Email: s.vanwijk@zuyderland.nl
- Phone: 088 - 459 9701
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
Preventing contrast-related kidney injury in people hospitalized with acute heart failure
This study tests whether a furosemide-based decongestion approach works better than standard IV saline to protect the kidneys of adults hospitalized with acute heart failure and moderate kidney dysfunction who need contrast scans.
-
Lung ultrasound and lactate at discharge to predict 30-day outcomes after acute heart failure
We’re testing whether a combination of lung ultrasound and blood lactate at discharge can help predict who will be readmitted or die within 30 days after leaving the hospital for acute heart failure.
-
Using urine sodium to guide IV diuretic dosing for hospitalized acute heart failure
This trial will test whether increasing IV diuretic doses to reach higher urine sodium levels helps hospitalized adults with acute decompensated heart failure remove more salt and fluid and have fewer readmissions.
-
Cardiac point-of-care ultrasound training pathway for emergency advanced practice providers
This project will test a simulation-based and just-in-time training program to teach emergency department nurse practitioners and physician assistants to perform focused cardiac POCUS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.